BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006;24:217-227. [PMID: 16365183 DOI: 10.1200/jco.2005.01.5388] [Cited by in Crossref: 306] [Cited by in F6Publishing: 119] [Article Influence: 19.1] [Reference Citation Analysis]
Number Citing Articles
1 Clarke S, Burge M, Cordwell C, Gibbs P, Reece W, Tebbutt N. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. BMC Cancer 2013;13:120. [PMID: 23497305 DOI: 10.1186/1471-2407-13-120] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
2 Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992-2998. [PMID: 18565886 DOI: 10.1200/jco.2007.15.9947.] [Reference Citation Analysis]
3 Strickler JH, Hurwitz HI. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist. 2012;17:513-524. [PMID: 22477726 DOI: 10.1634/theoncologist.2012-0003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
4 Leslie KK, Thiel KW, Goodheart MJ, De Geest K, Jia Y, Yang S. Endometrial cancer. Obstet Gynecol Clin North Am 2012;39:255-68. [PMID: 22640714 DOI: 10.1016/j.ogc.2012.04.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
5 Martins SF, Reis RM, Rodrigues AM, Baltazar F, Filho AL. Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. World J Clin Oncol 2011;2:272-80. [PMID: 21773077 DOI: 10.5306/wjco.v2.i6.272] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
6 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol 2007;13:6231-5. [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
7 McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs. 2008;68:487-506. [PMID: 18318567 DOI: 10.2165/00003495-200868040-00009] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
8 Jubb AM, Cesario A, Ferguson M, Congedo MT, Gatter KC, Lococo F, Mulè A, Pezzella F. Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. Br J Cancer 2011;104:1877-81. [PMID: 21540863 DOI: 10.1038/bjc.2011.147] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
9 Di Salvatore M, Pietrantonio F, Orlandi A, Del Re M, Berenato R, Rossi E, Caporale M, Guarino D, Martinetti A, Basso M, Mennitto R, Santonocito C, Mennitto A, Schinzari G, Bossi I, Capoluongo E, Danesi R, de Braud F, Barone C. IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. Oncotarget. 2017;8:16887-16898. [PMID: 28129643 DOI: 10.18632/oncotarget.14810] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
10 Akslen LA, Straume O, Geisler S, Sørlie T, Chi JT, Aas T, Børresen-Dale AL, Lønning PE. Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. Br J Cancer 2011;105:9-12. [PMID: 21673677 DOI: 10.1038/bjc.2011.203] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
11 Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 2010;1:12-25. [PMID: 21779425 DOI: 10.1177/1947601909356574] [Cited by in Crossref: 181] [Cited by in F6Publishing: 166] [Article Influence: 18.1] [Reference Citation Analysis]
12 Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8-18. [PMID: 20010945 DOI: 10.1038/sj.bjc.6605483] [Cited by in Crossref: 162] [Cited by in F6Publishing: 140] [Article Influence: 13.5] [Reference Citation Analysis]
13 Etienne-Grimaldi MC, Formento P, Degeorges A, Pierga JY, Delva R, Pivot X, Dalenc F, Espié M, Veyret C, Formento JL, Francoual M, Piutti M, de Crémoux P, Milano G. Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol 2011;71:921-8. [PMID: 21204912 DOI: 10.1111/j.1365-2125.2010.03896.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
14 Nazari A, Khorramdelazad H, Hassanshahi G. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer. Int J Clin Oncol 2017;22:991-1000. [PMID: 29022185 DOI: 10.1007/s10147-017-1187-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
15 Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol. 2008;5:206-219. [PMID: 18253104 DOI: 10.1038/ncponc1066] [Cited by in Crossref: 234] [Cited by in F6Publishing: 201] [Article Influence: 18.0] [Reference Citation Analysis]
16 Varey AH, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S, Dixon AR, Paraskeva C, Zaccheo O, Hassan AB. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer. 2008;98:1366-1379. [PMID: 18349829 DOI: 10.1038/sj.bjc.6604308] [Cited by in Crossref: 140] [Cited by in F6Publishing: 135] [Article Influence: 10.8] [Reference Citation Analysis]
17 Sun XF, Zhang H. Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. Mol Cancer 2006;5:43. [PMID: 17026740 DOI: 10.1186/1476-4598-5-43] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
18 Duda DG, Munn LL, Jain RK. Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling? J Natl Cancer Inst 2013;105:762-5. [PMID: 23670727 DOI: 10.1093/jnci/djt114] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
19 Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010;28:2817-2823. [PMID: 20458050 DOI: 10.1200/jco.2009.26.3988] [Cited by in Crossref: 375] [Cited by in F6Publishing: 206] [Article Influence: 34.1] [Reference Citation Analysis]
20 Galindo-Pumariño C, Collado M, Herrera M, Peña C. Tumor Microenvironment in Metastatic Colorectal Cancer: The Arbitrator in Patients' Outcome. Cancers (Basel) 2021;13:1130. [PMID: 33800796 DOI: 10.3390/cancers13051130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Wehland M, Bauer J, Magnusson NE, Infanger M, Grimm D. Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci 2013;14:9338-64. [PMID: 23629668 DOI: 10.3390/ijms14059338] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
22 Fischer I, Cunliffe CH, Bollo RJ, Raza S, Monoky D, Chiriboga L, Parker EC, Golfinos JG, Kelly PJ, Knopp EA, Gruber ML, Zagzag D, Narayana A. High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol 2008;10:700-8. [PMID: 18697955 DOI: 10.1215/15228517-2008-042] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.8] [Reference Citation Analysis]
23 Pircher A, Hilbe W, Heidegger I, Drevs J, Tichelli A, Medinger M. Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int J Mol Sci 2011;12:7077-99. [PMID: 22072937 DOI: 10.3390/ijms12107077] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
24 Klempner SJ, Myers AP, Mills GB, Westin SN. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother 2013;14:2171-82. [PMID: 23937415 DOI: 10.1517/14656566.2013.826650] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
25 Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther 2008;8:541-53. [PMID: 18352856 DOI: 10.1517/14712598.8.4.541] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 4.8] [Reference Citation Analysis]
26 Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol 2012;7:1361-8. [PMID: 22843087 DOI: 10.1097/JTO.0b013e318260e106] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
27 Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, Schiller JH. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009;27:6006-11. [PMID: 19826110 DOI: 10.1200/JCO.2009.23.7545] [Cited by in Crossref: 94] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
28 Rodriguez-Pascual J, Cubillo A. Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review. Curr Pharmacogenomics Person Med 2017;15:81-5. [PMID: 29657584 DOI: 10.2174/1875692115666170815161754] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
29 Yoshinaga M, Kitamura Y, Chaen T, Yamashita S, Tsuruta S, Hisano T, Ikeda Y, Sakai H, Nakamura K, Takayanagi R, Muto Y. The simultaneous expression of peroxisome proliferator-activated receptor delta and cyclooxygenase-2 may enhance angiogenesis and tumor venous invasion in tissues of colorectal cancers. Dig Dis Sci 2009;54:1108-14. [PMID: 18720000 DOI: 10.1007/s10620-008-0465-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
30 Torén W, Ansari D, Andersson R. Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: a systematic review and meta-analysis. Cancer Cell Int 2018;18:217. [PMID: 30602942 DOI: 10.1186/s12935-018-0715-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, Leek R, Tan EY, Singh B, Mortensen NJ. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer. 2009;101:1749-1757. [PMID: 19844231 DOI: 10.1038/sj.bjc.6605368] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 6.5] [Reference Citation Analysis]
32 Oguntade AS, Al-Amodi F, Alrumayh A, Alobaida M, Bwalya M. Anti-angiogenesis in cancer therapeutics: the magic bullet. J Egypt Natl Canc Inst 2021;33:15. [PMID: 34212275 DOI: 10.1186/s43046-021-00072-6] [Reference Citation Analysis]
33 Shin SJ, Hwang JW, Ahn JB, Rha SY, Roh JK, Chung HC. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. Invest New Drugs. 2013;31:1-13. [PMID: 22539090 DOI: 10.1007/s10637-012-9817-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
34 Paiva TF Jr, de Jesus VH, Marques RA, da Costa AA, de Macedo MP, Peresi PM, Damascena A, Rossi BM, Begnami MD, de Lima VC. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. BMC Cancer 2015;15:643. [PMID: 26394830 DOI: 10.1186/s12885-015-1648-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
35 Bai L, Wang F, Zhang DS, Li C, Jin Y, Wang DS, Chen DL, Qiu MZ, Luo HY, Wang ZQ, Li YH, Wang FH, Xu RH. A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer. Sci Rep 2015;5:17717. [PMID: 26620439 DOI: 10.1038/srep17717] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
36 Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95. [PMID: 17222792 DOI: 10.1016/j.ccr.2006.11.021] [Cited by in Crossref: 1336] [Cited by in F6Publishing: 1144] [Article Influence: 95.4] [Reference Citation Analysis]
37 Angelucci A, Delle Monache S, Cortellini A, Di Padova M, Ficorella C. "Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer. Int J Mol Sci 2018;19:E299. [PMID: 29351242 DOI: 10.3390/ijms19010299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
38 Jayson GC, Hicklin DJ, Ellis LM. Antiangiogenic therapy--evolving view based on clinical trial results. Nat Rev Clin Oncol 2012;9:297-303. [PMID: 22330688 DOI: 10.1038/nrclinonc.2012.8] [Cited by in Crossref: 105] [Cited by in F6Publishing: 82] [Article Influence: 11.7] [Reference Citation Analysis]
39 Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer. 2011;11:247. [PMID: 21669012 DOI: 10.1186/1471-2407-11-247] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
40 Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) 2013;6:988-1038. [PMID: 24276379 DOI: 10.3390/ph6080988] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
41 Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27:3020-3026. [PMID: 19470921 DOI: 10.1200/jco.2008.21.1771] [Cited by in Crossref: 382] [Cited by in F6Publishing: 187] [Article Influence: 31.8] [Reference Citation Analysis]
42 Aggarwal BB, Danda D, Gupta S, Gehlot P. Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol. 2009;78:1083-1094. [PMID: 19481061 DOI: 10.1016/j.bcp.2009.05.027] [Cited by in Crossref: 95] [Cited by in F6Publishing: 72] [Article Influence: 7.9] [Reference Citation Analysis]
43 Brar R, West R, Witten D, Raman B, Jacobs C, Ganjoo K. Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor. Case Rep Oncol 2009;2:242-50. [PMID: 20737044 DOI: 10.1159/000264637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
44 Kölbl AC, Birk AE, Kuhn C, Jeschke U, Andergassen U. Influence of VEGFR and LHCGR on endometrial adenocarcinoma. Oncol Lett 2016;12:2092-8. [PMID: 27625708 DOI: 10.3892/ol.2016.4906] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
45 Islam R, Chyou PH, Burmester JK. Modeling efficacy of bevacizumab treatment for metastatic colon cancer. J Cancer 2013;4:330-5. [PMID: 23678369 DOI: 10.7150/jca.6083] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
46 Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012;32:1095-111. [PMID: 23208836 DOI: 10.1002/phar.1147] [Cited by in Crossref: 120] [Cited by in F6Publishing: 89] [Article Influence: 15.0] [Reference Citation Analysis]
47 Holtz DO, Krafty RT, Mohamed-Hadley A, Zhang L, Alagkiozidis I, Leiby B, Guo W, Gimotty PA, Coukos G. Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. J Transl Med 2008;6:2. [PMID: 18182107 DOI: 10.1186/1479-5876-6-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
48 Rodriguez J, Zarate R, Bandres E, Viudez A, Chopitea A, García-Foncillas J, Gil-Bazo I. Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 2007;13:5867-76. [PMID: 17990352 DOI: 10.3748/wjg.v13.i44.5867] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
49 Zinser-Sierra JW, Rodríguez-Ramírez S, Villalobos-Valencia R, Ramírez-Márquez M. Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R D 2011;11:101-11. [PMID: 21679003 DOI: 10.2165/11590440-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
50 Yin X, Wang X, Shen B, Jing Y, Li Q, Cai MC, Gu Z, Yang Q, Zhang Z, Liu J, Li H, Di W, Zhuang G. A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis. Sci Rep 2016;6:31079. [PMID: 27498762 DOI: 10.1038/srep31079] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
51 Salazar R, Capdevila J, Laquente B, Manzano JL, Pericay C, Villacampa MM, López C, Losa F, Safont MJ, Gómez A, Alonso V, Escudero P, Gallego J, Sastre J, Grávalos C, Biondo S, Palacios A, Aranda E. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer 2015;15:60. [PMID: 25886378 DOI: 10.1186/s12885-015-1053-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
52 Mulcahy MF. Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics 2008;2:53-9. [PMID: 19707427 DOI: 10.2147/btt.s1519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
53 Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 2010;39:601-13. [PMID: 20951919 DOI: 10.1016/j.gtc.2010.08.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
54 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007;13:6231-6235. [PMID: 18069765 DOI: 10.3748/wjg.13.6231] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
55 Ahluwalia MS, Gladson CL. Progress on antiangiogenic therapy for patients with malignant glioma. J Oncol 2010;2010:689018. [PMID: 20379377 DOI: 10.1155/2010/689018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
56 Abid MN, Qadir FA, Salihi A. Association between the serum concentrations and mutational status of IL-8, IL-27 and VEGF and the expression levels of the hERG potassium channel gene in patients with colorectal cancer. Oncol Lett 2021;22:665. [PMID: 34386087 DOI: 10.3892/ol.2021.12926] [Reference Citation Analysis]
57 Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91:1071-1121. [PMID: 21742796 DOI: 10.1152/physrev.00038.2010] [Cited by in Crossref: 887] [Cited by in F6Publishing: 791] [Article Influence: 88.7] [Reference Citation Analysis]
58 Pories SE, Wulf GM. Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review. Breast Cancer (Dove Med Press) 2010;2:37-44. [PMID: 24367165 DOI: 10.2147/bctt.s6511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
59 Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, Oh JH, Kim BC, Sohn DK, Kim DY, Chang HJ. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009;9:246. [PMID: 19619339 DOI: 10.1186/1471-2407-9-246] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
60 Bais C, Mueller B, Brady MF, Mannel RS, Burger RA, Wei W, Marien KM, Kockx MM, Husain A, Birrer MJ; NRG Oncology/Gynecologic Oncology Group. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. J Natl Cancer Inst 2017;109. [PMID: 29059426 DOI: 10.1093/jnci/djx066] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
61 Jürgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer. 2013;108:1316-1323. [PMID: 23449351 DOI: 10.1038/bjc.2013.79] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
62 Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O'Dwyer PJ, Giantonio BJ, Meropol NJ, Benson AB, Harper SJ. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res 2012;18:6384-91. [PMID: 23104894 DOI: 10.1158/1078-0432.CCR-12-2223] [Cited by in Crossref: 47] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
63 Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol 2010;119:484-90. [PMID: 20870280 DOI: 10.1016/j.ygyno.2010.08.016] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
64 Zhu B, Xu T, Yuan J, Guo X, Liu D. Transcriptome sequencing reveals differences between primary and secondary hair follicle-derived dermal papilla cells of the Cashmere goat (Capra hircus). PLoS One 2013;8:e76282. [PMID: 24069460 DOI: 10.1371/journal.pone.0076282] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
65 Lind JS, Smit EF. Angiogenesis inhibitors in the treatment of non-small cell lung cancer. Ther Adv Med Oncol 2009;1:95-107. [PMID: 21789115 DOI: 10.1177/1758834009338633] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
66 Nandikolla AG, Rajdev L. Targeting angiogenesis in gastrointestinal tumors: current challenges. Transl Gastroenterol Hepatol 2016;1:67. [PMID: 28138633 DOI: 10.21037/tgh.2016.08.04] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
67 Noonan SA, Morrissey ME, Martin P, Biniecka M, Ó'Meachair S, Maguire A, Tosetto M, Nolan B, Hyland J, Sheahan K, O'Donoghue D, Mulcahy H, Fennelly D, O'Sullivan J. Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment. Oncotarget 2018;9:10536-48. [PMID: 29535825 DOI: 10.18632/oncotarget.24276] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
68 Ramnefjell M, Aamelfot C, Aziz S, Helgeland L, Akslen LA. Microvascular proliferation is associated with aggressive tumour features and reduced survival in lung adenocarcinoma. J Pathol Clin Res 2017;3:249-57. [PMID: 29085665 DOI: 10.1002/cjp2.78] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
69 Westin SN, Broaddus RR. Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther. 2012;13:1-13. [PMID: 22198566 DOI: 10.4161/cbt.13.1.18438] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
70 Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992-2998. [PMID: 18565886 DOI: 10.1200/jco.2007.15.9947] [Cited by in Crossref: 317] [Cited by in F6Publishing: 141] [Article Influence: 24.4] [Reference Citation Analysis]
71 Truelsen SLB, Mousavi N, Wei H, Harvey L, Stausholm R, Spillum E, Hagel G, Qvortrup K, Thastrup O, Harling H, Mellor H, Thastrup J. The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids. PLoS One 2021;16:e0253258. [PMID: 34234354 DOI: 10.1371/journal.pone.0253258] [Reference Citation Analysis]
72 Duda DG. Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. ISRN Cell Biol 2012;2012:587259. [PMID: 24340224 DOI: 10.5402/2012/587259] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
73 Ryanne Wu R, Lindenberg PA, Slack R, Noone AM, Marshall JL, He AR. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer. 2009;40:101-108. [PMID: 19921473 DOI: 10.1007/s12029-009-9104-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
74 Gavalas NG, Liontos M, Trachana SP, Bagratuni T, Arapinis C, Liacos C, Dimopoulos MA, Bamias A. Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci 2013;14:15885-909. [PMID: 23903048 DOI: 10.3390/ijms140815885] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 7.4] [Reference Citation Analysis]
75 Sümbül AT, Dişel U, Sezgin N, Sezer A, Köse F, Beşen AA, Sümbül Z, Abalı H, Özyılkan Ö. Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment? Med Sci Monit 2014;20:428-33. [PMID: 24632679 DOI: 10.12659/MSM.889945] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
76 Kanthou C, Tozer G. Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy. Br J Radiol 2019;92:20180405. [PMID: 30160184 DOI: 10.1259/bjr.20180405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
77 Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. J Clin Oncol 2015;33:2735-44. [PMID: 26124478 DOI: 10.1200/JCO.2015.61.5005] [Cited by in Crossref: 182] [Cited by in F6Publishing: 100] [Article Influence: 30.3] [Reference Citation Analysis]
78 Crona D, Innocenti F. Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark Med 2012;6:349-62. [PMID: 22731909 DOI: 10.2217/bmm.12.19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
79 Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6:327-338. [PMID: 19483739 DOI: 10.1038/nrclinonc.2009.63] [Cited by in Crossref: 435] [Cited by in F6Publishing: 375] [Article Influence: 36.3] [Reference Citation Analysis]
80 Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, Low I, Blades J, Li JL, Allen P, Leek R. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol. 2010;176:2019-2028. [PMID: 20167860 DOI: 10.2353/ajpath.2010.090908] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 7.0] [Reference Citation Analysis]
81 Jary M, Vernerey D, Lecomte T, Dobi E, Ghiringhelli F, Monnien F, Godet Y, Kim S, Bouché O, Fratte S, Gonçalves A, Leger J, Queiroz L, Adotevi O, Bonnetain F, Borg C. Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma. Cancer Epidemiol Biomarkers Prev 2015;24:603-12. [PMID: 25583947 DOI: 10.1158/1055-9965.EPI-14-1059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
82 Weickhardt AJ, Williams DS, Lee CK, Chionh F, Simes J, Murone C, Wilson K, Parry MM, Asadi K, Scott AM, Punt CJ, Nagtegaal ID, Price TJ, Mariadason JM, Tebbutt NC. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. Br J Cancer 2015;113:37-45. [PMID: 26125443 DOI: 10.1038/bjc.2015.209] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
83 Semrad TJ, Kim EJ. Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. J Gastrointest Oncol. 2016;7:S11-S20. [PMID: 27034809 DOI: 10.3978/j.issn.2078-6891.2015.094] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
84 Mousa L, Salem ME, Mikhail S. Biomarkers of Angiogenesis in Colorectal Cancer. Biomark Cancer 2015;7:13-9. [PMID: 26543385 DOI: 10.4137/BIC.S25250] [Cited by in Crossref: 18] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
85 Cidon EU, Alonso P, Masters B. Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next? Clin Med Insights Oncol 2016;10:41-55. [PMID: 27147901 DOI: 10.4137/CMO.S34542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
86 Bianconi D, Herac M, Posch F, Schmeidl M, Unseld M, Kieler M, Brettner R, Müllauer L, Riedl J, Gerger A, Scheithauer W, Prager G. Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. Ther Adv Med Oncol 2020;12:1758835920928635. [PMID: 32922518 DOI: 10.1177/1758835920928635] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
87 Yang SX, Steinberg SM, Nguyen D, Wu TD, Modrusan Z, Swain SM. Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res. 2008;14:5893-5899. [PMID: 18794102 DOI: 10.1158/1078-0432.ccr-07-4762] [Cited by in Crossref: 68] [Cited by in F6Publishing: 37] [Article Influence: 5.2] [Reference Citation Analysis]
88 Rosa B, de Jesus JP, de Mello EL, Cesar D, Correia MM. Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. Ecancermedicalscience 2015;9:582. [PMID: 26557880 DOI: 10.3332/ecancer.2015.582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
89 Ch'ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol 2015;7:2029-40. [PMID: 26261692 DOI: 10.4254/wjh.v7.i16.2029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
90 Han K, Claret L, Piao Y, Hegde P, Joshi A, Powell JR, Jin J, Bruno R. Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A. CPT Pharmacometrics Syst Pharmacol 2016;5:352-8. [PMID: 27404946 DOI: 10.1002/psp4.12064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
91 Verstraete M, Debucquoy A, Dekervel J, van Pelt J, Verslype C, Devos E, Chiritescu G, Dumon K, D'Hoore A, Gevaert O, Sagaert X, Van Cutsem E, Haustermans K. Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial. Br J Cancer 2015;112:1314-25. [PMID: 25867261 DOI: 10.1038/bjc.2015.93] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
92 Hansen TF, Kjær-Frifeldt S, Morgenthaler S, Blondal T, Lindebjerg J, Jakobsen A, Sørensen FB. The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort. J Transl Med 2014;12:254. [PMID: 25199818 DOI: 10.1186/s12967-014-0254-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
93 Marisi G, Scarpi E, Passardi A, Nanni O, Ragazzini A, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P. Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. Sci Rep. 2017;7:1293. [PMID: 28465540 DOI: 10.1038/s41598-017-01420-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
94 Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 2011;17:372-81. [PMID: 21224365 DOI: 10.1158/1078-0432.CCR-10-1791] [Cited by in Crossref: 77] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
95 Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD; ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-8. [PMID: 18824714 DOI: 10.1200/JCO.2008.16.1612] [Cited by in Crossref: 476] [Cited by in F6Publishing: 216] [Article Influence: 36.6] [Reference Citation Analysis]
96 Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL, Perret GY. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006;94:1823-32. [PMID: 16773076 DOI: 10.1038/sj.bjc.6603176] [Cited by in Crossref: 238] [Cited by in F6Publishing: 214] [Article Influence: 15.9] [Reference Citation Analysis]
97 Madu CO, Wang S, Madu CO, Lu Y. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. J Cancer 2020;11:4474-94. [PMID: 32489466 DOI: 10.7150/jca.44313] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
98 Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, Grenga I, Schirru M, Guadagni F, Roselli M. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis 2011;26:143-51. [PMID: 21188390 DOI: 10.1007/s00384-010-1108-1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
99 Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Barni S. KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. Med Oncol. 2013;30:650. [PMID: 23828442 DOI: 10.1007/s12032-013-0650-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
100 Shibata Y, Kobayashi N, Sato T, Nakashima K, Kaneko T. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer. Thorac Cancer 2020;11:1258-64. [PMID: 32163231 DOI: 10.1111/1759-7714.13387] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
101 Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R. Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. Oncotarget 2017;8:42949-61. [PMID: 28487489 DOI: 10.18632/oncotarget.17306] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
102 Marien KM, Croons V, Waumans Y, Sluydts E, De Schepper S, Andries L, Waelput W, Fransen E, Vermeulen PB, Kockx MM, De Meyer GR. Development and Validation of a Histological Method to Measure Microvessel Density in Whole-Slide Images of Cancer Tissue. PLoS One 2016;11:e0161496. [PMID: 27583442 DOI: 10.1371/journal.pone.0161496] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
103 Bottos A, Bardelli A. Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy? Cell Mol Life Sci 2013;70:4131-40. [PMID: 23685900 DOI: 10.1007/s00018-013-1331-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
104 Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012;2:a006577. [PMID: 23028128 DOI: 10.1101/cshperspect.a006577] [Cited by in Crossref: 132] [Cited by in F6Publishing: 110] [Article Influence: 14.7] [Reference Citation Analysis]
105 Wang J, Lu Y, Wang J, Koch AE, Zhang J, Taichman RS. CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res 2008;68:10367-76. [PMID: 19074906 DOI: 10.1158/0008-5472.CAN-08-2780] [Cited by in Crossref: 84] [Cited by in F6Publishing: 55] [Article Influence: 7.0] [Reference Citation Analysis]
106 Schneider BP, Shen F, Miller KD. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol 2012;13:e427-36. [PMID: 23026828 DOI: 10.1016/S1470-2045(12)70275-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
107 Guijarro-Muñoz I, Sánchez A, Martínez-Martínez E, García JM, Salas C, Provencio M, Alvarez-Vallina L, Sanz L. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Med Oncol 2013;30:572. [PMID: 23579861 DOI: 10.1007/s12032-013-0572-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
108 Yan Y, Grothey A. Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. Onco Targets Ther 2015;8:2949-57. [PMID: 26508880 DOI: 10.2147/OTT.S79145] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
109 Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007;13:223-30. [PMID: 17462954 DOI: 10.1016/j.molmed.2007.04.001] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 7.3] [Reference Citation Analysis]
110 Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010;103:1407-1414. [PMID: 20924372 DOI: 10.1038/sj.bjc.6605925] [Cited by in Crossref: 112] [Cited by in F6Publishing: 99] [Article Influence: 10.2] [Reference Citation Analysis]
111 Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015;7:2245-63. [PMID: 26380650 DOI: 10.4254/wjh.v7.i20.2245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
112 Pitts TM, Tan AC, Kulikowski GN, Tentler JJ, Brown AM, Flanigan SA, Leong S, Coldren CD, Hirsch FR, Varella-Garcia M, Korch C, Eckhardt SG. Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res 2010;16:3193-204. [PMID: 20530704 DOI: 10.1158/1078-0432.CCR-09-3191] [Cited by in Crossref: 57] [Cited by in F6Publishing: 41] [Article Influence: 5.2] [Reference Citation Analysis]
113 Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, de Braud F, Gevorgyan A, Dotti KF, Bajetta E, Campiglio M, Bianchi F, Bregni G, Pietrantonio F. Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. Cancers (Basel) 2014;6:1753-68. [PMID: 25256831 DOI: 10.3390/cancers6031753] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
114 Wang Y, Yao X, Ge J, Hu F, Zhao Y. Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis. ScientificWorldJournal. 2014;2014:102736. [PMID: 25143961 DOI: 10.1155/2014/102736] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
115 Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271-8. [PMID: 18182667 DOI: 10.1200/JCO.2007.13.3652] [Cited by in Crossref: 205] [Cited by in F6Publishing: 106] [Article Influence: 15.8] [Reference Citation Analysis]
116 Lin D, Alborn WE, Slebos RJ, Liebler DC. Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma. J Proteome Res 2013;12:5996-6003. [PMID: 24224610 DOI: 10.1021/pr400877e] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
117 Chan A. Antiangiogenic therapy for metastatic breast cancer: current status and future directions. Drugs 2009;69:167-81. [PMID: 19228074 DOI: 10.2165/00003495-200969020-00003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
118 Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012;7:e35629. [PMID: 22539986 DOI: 10.1371/journal.pone.0035629] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
119 Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, Meinhardt G, Harris AL; Tumour and Angiogenesis Research Group. Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. Br J Cancer 2012;107:1044-50. [PMID: 22910317 DOI: 10.1038/bjc.2012.369] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]